- DALFAMPRIDINE IN MULTIPLE SCLEROSIS
[作者：Goodman, AD; Hyland, M,期刊：Drugs of today, 页码：635-639 , 文章类型： Article，,卷期：2010年46-9]
- Dalfampridine (4-aminopyridine or 4-AP) is a potassium channel blocker that is historically known in the literature as fampridine (INN). This review begins with an outline of the pharmacology and pharmacokinetics. Early ...
- ERIBULIN MESILATE, A HALICHONDRIN B ANALOGUE, IN THE TREATMENT OF BREAST CANCER
[作者：Mani, S; Swami, U,期刊：Drugs of today, 页码：641-653 , 文章类型： Article，,卷期：2010年46-9]
- Eisai is developing eribulin mesilate (E-7389), a synthetic macrocyclic ketone analogue of the tubulin inhibitor halichondrin B, for the treatment of a variety of solid tumors that include but are not limited to breast a...
- ULIPRISTAL ACETATE FOR EMERGENCY CONTRACEPTION
[作者：Russo, JA; Creinin, MD,期刊：Drugs of today, 页码：655-660 , 文章类型： Article，,卷期：2010年46-9]
- Ulipristal acetate is a progesterone receptor modulator. As an emergency contraceptive, a 30-mg micronized formulation is effective for use up to 120 h from unprotected sexual intercourse. Ulipristal acetate acts as an a...
- BIOLOGICAL MARKERS IN SCHIZOPHRENIA: AN UPDATE
[作者：Madaan, V; Bestha, DP; Kolli, VB,期刊：Drugs of today, 页码：661-669 , 文章类型： Review，,卷期：2010年46-9]
- Biological markers are quantitative measures that allow clinicians to diagnose and assess the disease process, monitor response to treatment and may, to some extent, assist with prognostic assessments (1). Biological mar...
- BOTULINUM TOXIN TYPE A: EXPLORING NEW INDICATIONS
[作者：Brashear, A,期刊：Drugs of today, 页码：671-682 , 文章类型： Review，,卷期：2010年46-9]
- The use of botulinum toxin has expanded in the last five years to include traditional neurological use against dystonia and spasticity, as well as the emerging use for headache, pain, neuropathy, myofascial pain, joint a...
- VANDETANIB: AN OVERVIEW OF ITS CLINICAL DEVELOPMENT IN NSCLC AND OTHER TUMORS
[作者：Morabito, A; Piccirillo, MC; Costanzo, R; Sandomenico, C; Carillio, G; Daniele, G; Giordano, P; Bryce, J; Carotenuto, P; La Rocca, A; Di Maio, M; Normanno, N; Rocco, G; Perrone, F,期刊：Drugs of today, 页码：683-698 , 文章类型： Review，,卷期：2010年46-9]
- Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR) and Ret tyrosine kinases involved in tumor growth, progression and angiogenesis. Phase I...
|